NEW LISTING ANIL SATWANI, SYMBIOTEC PHARMALAB Says Starting This… — Fundamental Analysis (Long term)

Fundamental Analysis (Long term)@fundamental3 · 45K subscribers Open in TelegramOpen

NEW LISTING

ANIL SATWANI, SYMBIOTEC PHARMALAB Says

Starting This Year, CDMO Business Will Contribute To Revenues
Have Recently Made ₹850 Cr Investment

Have Clocked More Than 1x Asset Turnover, Will Maintain That

Base API Biz Is Of ₹1,000 Cr & Growing, Will Continue To Be The Largest In Our Segment

Expect 40% From Base Biz & Rest Equally Split B/W Injectable & CDMO Biz In 5 years

t.me/fundamental3/58934